Principal Financial Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Principal Financial Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-167,475	Closed	-$18M	–	2543
2023 Q1	$18M	Buy	167,475 +157,166	+1,525%	+$18.1M	0.01%	912
2022 Q4	$1.13M	Buy	10,309 +1,404	+16%	+$91K	﹤0.01%	1844
2022 Q3	$526K	Sell	8,905 -5	-0.1%	-$229	﹤0.01%	1948
2022 Q2	$251K	Buy	+8,910	New	+$258K	﹤0.01%	2232

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Principal Financial Group's RXDX Position: Q2 2023 in Review

Principal Financial Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 167,475 shares — an estimated $18M sold.

Principal Financial Group first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $18M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Principal Financial Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Principal Financial Group sold 167,475 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $18M.
Principal Financial Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Principal Financial Group's Prometheus Biosciences, Inc. Common Stock position peaked at $18M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Principal Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.